Gilead Sciences's Remdesivir may cut Covid-19 risk of death by 62% | Sharecast.com
Third phase clinical trial data presented by the company at the 23rd International AIDS conference showed that the treatment was associated with a 62% reduction in the risk of mortality and an improvement in clinical recovery.
However, the biotechnology company said the finding needed to be confirmed through prospective clinical trials.
